About Us
Healthcare innovations stall not because the science is weak, but because evidence expectations are fragmented, implicit, and inconsistent across payers. Companies generate analytical, clinical, and real-world data—but lack a clear understanding of what evidence truly matters, which gaps will block coverage, or what actions will accelerate adoption. This misalignment slows progress and keeps clinically meaningful technologies from reaching patients who need them.
Savvyn is building the evidence-intelligence layer for healthcare innovation: a structured, transparent system that maps evidence to payer expectations and clarifies the pathway from validation to real-world impact. At the core is the Savvyn Intelligence Layer—a reasoning engine that unifies analytical validity, clinical validity, clinical utility, real-world outcomes, and policy precedent. This intelligence powers Savvyn’s product surfaces (Docs, Data, and Dash), transforming complexity into clear, prescriptive guidance on what to do next to strengthen coverage readiness and accelerate adoption.
Savvyn’s foundation is deep oncology expertise—decades of work across cancer biology, diagnostics, evidence generation, and payer strategy. That experience makes oncology the natural first vertical: evidence requirements are more complex, payer variation is more consequential, and the gap between clinical validity and clinical access is widest.
We believe the future of healthcare depends on more predictable, evidence-aligned access pathways. Savvyn exists to make those pathways visible, actionable, and equitable—so when a technology becomes clinically meaningful, patients can actually receive it.
Meet Our Founder
Catherine Del Vecchio Fitz, PhD, MSM is the founder and CEO of Savvyn Insights. Her career spans science, medicine, and operations—advancing early cancer detection, precision oncology, and data-driven innovation across research and real-world clinical settings.
A Stanford- and MIT-trained cancer biologist, she brings scientific rigor shaped by work in translational oncology and molecular diagnostics. Her operational leadership across clinical development, medical affairs, and data strategy gives her a clear view of how evidence is generated, interpreted, and used in payer and clinical decision-making—and where the process breaks down for innovators.
Catherine has built and led cross-functional teams, helped scale an early-stage diagnostics company into a growth-stage organization, and partnered closely with community and academic oncology programs. She has seen how even strong science can stall when evidence is fragmented or misaligned—and founded Savvyn to solve that systemic barrier.
She holds a BA in Biology from Bowdoin College, a PhD in Cancer Biology and a Master of Science in Medicine from Stanford University, completed postdoctoral training at MIT, and is an alum of Harvard Business School’s Program for Leadership Development. A Maine native, she is committed to contributing to her home state’s growing innovation ecosystem.
As a scientist and operator, she believes time is the most valuable resource we have—and builds solutions that make work smarter, faster, and relentlessly efficient.